A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
Public ClinicalTrials.gov record NCT03275389. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Reactogenicity, Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults
Study identification
- NCT ID
- NCT03275389
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 470 participants
Conditions and interventions
Conditions
Interventions
- D-SUIV cH8/1N1+AS03 Biological
- D-SUIV cH5/1N1+AS03 Biological
- D-SUIV cH11/1N1+AS03 Biological
- D-SUIV cH8/1N1+AS01 Biological
- D-SUIV cH5/1N1+AS01 Biological
- D-SUIV cH11/1N1+AS01 Biological
- D-SUIV cH8/1N1 Biological
- D-SUIV cH5/1N1 Biological
- D-SUIV cH11/1N1 Biological
- Placebo Biological
- Fluarix Quadrivalent Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 39 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 7, 2017
- Primary completion
- Mar 25, 2020
- Completion
- Mar 25, 2020
- Last update posted
- May 6, 2021
2017 – 2020
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | South Miami | Florida | 33143 | — |
| GSK Investigational Site | Wichita | Kansas | 67207 | — |
| GSK Investigational Site | Rochester | New York | 14609 | — |
| GSK Investigational Site | Austin | Texas | 78705 | — |
| GSK Investigational Site | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03275389, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2021 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03275389 live on ClinicalTrials.gov.